LEXINGTON, Mass.--(BUSINESS WIRE)--
Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has
been selected for addition to the NASDAQ Biotechnology Index (NASDAQ:
NBI) effective prior to the market open on Monday, December 18, 2017.
The NASDAQ Biotechnology Index is designed to track the performance of a
set of NASDAQ-listed securities that are classified as either
biotechnology or pharmaceutical according to the Industry Classification
Benchmark. The NASDAQ Biotechnology Index is re-ranked annually. For
more information about the NASDAQ Biotechnology Index visit indexes.nasdaqomx.com.
Pharmaceuticals is a clinical stage biopharmaceutical company
focused on applying its DCE
Platform® (deuterated chemical entity platform) to create novel
medicines designed to address unmet patient needs. The Company's
approach starts with approved drugs in which deuterium substitution has
the potential to enhance clinical safety, tolerability or efficacy.
Concert has a broad
pipeline of innovative medicines targeting autoimmune and
inflammatory diseases and central nervous systems (CNS) disorders. For
more information please visit www.concertpharma.com.
Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and
DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171213005089/en/
Concert Pharmaceuticals, Inc.
The Yates Network
Kathryn Morris, 914-204-6412
Source: Concert Pharmaceuticals, Inc.
News Provided by Acquire Media